← All trials
NCT07030595
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 12, 2023
- Primary completion
- Oct 2, 2024
- Completion date
- May 30, 2025
- First posted
- Jun 22, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 474
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alebund PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.